Sagimet Biosciences Inc. Series A (SGMT) Stock Forecast: StockMap's 2-Week Call
SGMT stock forecast: StockMap's model makes no two-week call on Sagimet Biosciences Inc. Series A after the Nov 19 close: its evidence is split, 3 reasons for and 12 against. Right in 2 of 4 two-week windows on SGMT since Aug 21; by chance, a call on the same dates was right 69% of the time.
Sagimet Biosciences Inc. Series A last closed at $9.62, -4.85% on the session.
Against the IVW growth benchmark the position is -2.52% over the forecast window.
Sagimet Biosciences Inc. Series A's market cap is $686.54M as of November 19, 2026.
No call today: the model sees no clear direction · the next 2 weeks, vs S&P 500 growth. The lean on a scale from −100 to +100 is -15 (too close to call).
Where SGMT sits: sized by market cap, coloured by the day's move.
The read is built from 15 underlying insights — 3 bullish and 12 bearish.
Agreement across those insights is 80%.
27 daily calls for SGMT so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.
On the fundamentals StockMap ranks Sagimet Biosciences Inc. Series A in the 23rd percentile on return on equity, where 100 is best.
Sagimet Biosciences Inc. Series A is classified under Health Care / Biotechnology.
StockMap tracks Sagimet Biosciences Inc. Series A as the 147th largest of the 394 companies it covers in the Biotechnology industry, part of the Health Care sector.
Across that group the current two-week reads are 200 Moderate Underperform, 134 Neutral, 43 Strong Underperform and 17 Moderate Outperform.
On that composite Sagimet Biosciences Inc. Series A ranks 138th of 394 in the group, against a group median of -0.27.